IGM Biosciences(IGMS) - 2021 Q3 - Quarterly Report

Financial Performance - The company reported a net loss of $114.5 million for the nine months ended September 30, 2021, compared to a net loss of $56.7 million for the same period in 2020, reflecting an increase of $57.8 million [91]. - The total operating expenses for the nine months ended September 30, 2021, were $114.6 million, compared to $58.5 million for the same period in 2020, an increase of $56.1 million [111]. - As of September 30, 2021, the company had an accumulated deficit of $303.1 million, primarily due to research and development costs [91]. - Net cash used in operating activities was $89.4 million for the nine months ended September 30, 2021, compared to $44.5 million in 2020, indicating a significant increase in cash outflow [122]. - Other income, net decreased to $0.1 million for the nine months ended September 30, 2021, from $1.8 million in 2020, primarily due to lower interest earned [116]. Research and Development - Research and development expenses for the three months ended September 30, 2021, were $34.2 million, up from $15.8 million in the same period in 2020, representing an increase of $18.4 million [106]. - Research and development expenses increased to $87.9 million for the nine months ended September 30, 2021, up from $45.4 million in 2020, representing a $42.4 million increase [112]. - Preclinical stage program expenses rose by $20.1 million, driven by an $8.4 million increase in activities related to IGM-6268 and an $11.7 million increase in discovery and other programs [113]. - The company has created a proprietary IgM antibody technology platform aimed at developing treatments for various diseases, including oncology and infectious diseases [88]. - The company plans to continue advancing the development of multiple product candidates, including IGM-2323 and IGM-8444, which are currently in clinical trials [92]. Administrative Expenses - General and administrative expenses increased to $10.0 million for the three months ended September 30, 2021, from $4.7 million in the same period in 2020, an increase of $5.3 million [109]. - General and administrative expenses were $26.8 million for the nine months ended September 30, 2021, compared to $13.1 million in 2020, reflecting a $13.7 million increase primarily due to personnel-related expenses [115]. Funding and Capital Requirements - The company expects significant increases in expenses and capital requirements as it expands its pipeline and manufacturing capabilities [92]. - The company plans to seek additional funding through public or private equity offerings, debt financings, and collaborations, with a maximum aggregate amount of $400 million available under a shelf registration statement [119]. - The company entered into a lease amendment in July 2021, committing to minimum payments totaling $31.8 million through June 2032 [128]. Cash and Investments - As of September 30, 2021, the company had cash and investments totaling $265.6 million and an accumulated deficit of $303.1 million [117]. - Net cash provided by investing activities was $13.0 million for the nine months ended September 30, 2021, down from $37.1 million in 2020 [124].